PHAR · Pharming Group N.V.
$10.75
-1.26 (-10.49%)
At close · Jul 30
Market Cap
$7.54B
Shares
701.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.75
Open$9.65
Day$9.62–10.75
52W$9.54–21.34
Avg vol 30d7K
Short int10K · 0.0% float · 1.5d
Short vol69%
Last earningsJul 30, 2026
DataDec 2020–Jul 2026
Up next
Next earnings call
Nov 14, 2026
Est · unconfirmed
· in 15 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−18%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−33%
trailing
YTD return
−39%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
3 of 12 funds reported for Jun 30 · net +8.7K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +210.4% MoM · 1.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
12 holders — near 3-yr high, broad support
Squeeze score
44
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Revenue
· 2026
Initiated
$405M – $425M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
3 of 12 funds reported for Jun 30 · net +8.7K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +210.4% MoM · 1.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
12 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $11 · 10%
52-wk high $21
vs 200-day avg -31%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHAR
this stock
Pharming Group N.V.
|
$7.54B | -39.2% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$465.49B | +6.0% | +22179.2% | 947.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.26B | +6.3% | +46.2% | 28.6 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.02B | -4.2% | +20.8% | 18.3 | 3.4% |
|
ARGX
Argenx SE
|
$53.42B | +3.8% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHAR | -18.4% | -21.3% | -33.0% | -22.6% | -39.2% |
| SPY | +0.5% | -0.6% | +9.5% | -0.7% | +8.8% |
| vs SPY | -18.9% | -20.7% | -42.4% | -21.9% | -47.9% |